S&P 500 Futures
(0.87%) 5 126.25 points
Dow Jones Futures
(0.20%) 38 364 points
Nasdaq Futures
(1.17%) 17 772 points
Oil
(0.50%) $83.99
Gas
(-2.63%) $1.595
Gold
(0.41%) $2 352.00
Silver
(1.09%) $27.65
Platinum
(1.41%) $933.50
USD/EUR
(-0.02%) $0.932
USD/NOK
(0.01%) $10.95
USD/GBP
(-0.01%) $0.799
USD/RUB
(0.01%) $92.18

Realtime updates for Infant Bacterial [IBT-B.ST]

Exchange: STO Sector: Healthcare Industry: Biotechnology
Last Updated25 Apr 2024 @ 09:57

-0.46% SEK 87.40

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 09:57):

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden...

Stats
Today's Volume 914.00
Average Volume 6 633.00
Market Cap 1.14B
EPS SEK0 ( 2024-02-07 )
Next earnings date ( SEK0 ) 2024-05-06
Last Dividend SEK0 ( N/A )
Next Dividend SEK0 ( N/A )
P/E -8.78
ATR14 SEK1.146 (1.31%)

Infant Bacterial Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Infant Bacterial Financials

Annual 2023
Revenue: SEK77 000.00
Gross Profit: SEK77 000.00 (100.00 %)
EPS: SEK-9.95
Q4 2023
Revenue: SEK0
Gross Profit: SEK0 (0.00 %)
EPS: SEK-3.04
Q3 2023
Revenue: SEK64 000.00
Gross Profit: SEK64 000.00 (100.00 %)
EPS: SEK-2.31
Q2 2023
Revenue: SEK0
Gross Profit: SEK0 (0.00 %)
EPS: SEK-2.57

Financial Reports:

No articles found.

Infant Bacterial

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators